|
rs12917707
|
|
|
0.720 |
GeneticVariation |
BEFREE |
We tested a large cohort of Caucasian patients for association of rs12917707 with IgA nephropathy showing a benign, stable course and with IgA nephropathy that progressed toward end stage renal failure.
|
25163389 |
2014 |
|
rs12917707
|
|
|
0.720 |
GeneticVariation |
BEFREE |
The rs12917707 minor allele showed association with lower risk of ESRD (OR 0.89 [0.76-1.03], p = 0.04) consistent in effect size and direction with the previous report (Böger et al, PLoS Genet 2011).
|
22947327 |
2012 |
|
rs73885319
|
|
|
0.720 |
GeneticVariation |
BEFREE |
We use recently released sequences from the 1000 Genomes Project to identify two western African-specific missense mutations (S342G and I384M) in the neighboring APOL1 gene, and demonstrate that these are more strongly associated with ESKD than previously reported MYH9 variants.
|
20635188 |
2010 |
|
rs73885319
|
|
|
0.720 |
GeneticVariation |
BEFREE |
Several variants at the <i>APOL1</i> locus were associated with ESKD including the <i>APOL1</i> G1 rs73885319 (<i>p</i> = 1.2 × 10<sup>-9</sup>).
|
31178898 |
2019 |
|
rs1217691063
|
|
|
0.100 |
GeneticVariation |
BEFREE |
The frequency of MTHFR 1298CC genotype was significantly higher in ESRD patients than in controls (21.4% vs. 2.9%); the frequency of the MTHFR C677T genotypes did not differ between groups (26.1% vs. 17.4%).
|
17899317 |
2008 |
|
rs1217691063
|
|
|
0.100 |
GeneticVariation |
BEFREE |
To evaluate the respective roles of residual glomerular filtration (by measuring a specific protein marker, cystatin C), genetic polymorphisms and nutritional status in tHcy blood levels in end-stage renal disease patients (ESRD) under hemodialysis and supplemented with folate, we measured tHcy, folate, vitamin B12 (B12), creatinine, cystatin C, albumin and C-reactive protein and determined the polymorphism of methylenetetrahydrofolate reductase (MTHFR) (C677T and A1289C) and of methionine synthase (MS) (A2756G) in 114 ESRD patients before hemodialysis and 76 control subjects.
|
11592445 |
2001 |
|
rs1217691063
|
|
|
0.100 |
GeneticVariation |
BEFREE |
The carrier of FVL, TT genotype of C677T, and CC genotype of A1298C polymorphisms may act as risk factors for ESRD.
|
19520684 |
2010 |
|
rs1217691063
|
|
|
0.100 |
GeneticVariation |
BEFREE |
Our results did not show any association between the MTHFR reductase C677T polymorphism and the increased risk of the development of end-stage renal disease.
|
12187113 |
2002 |
|
rs1217691063
|
|
|
0.100 |
GeneticVariation |
BEFREE |
The C677T mutation of the MTHFR gene may be an independent risk factor that predicts the development of carotid atherosclerosis in ESRD patients.
|
11287760 |
2001 |
|
rs1217691063
|
|
|
0.100 |
GeneticVariation |
BEFREE |
Although the frequencies of the CT and TT genotypes of the C677T polymorphism tended to increase with each stage of diabetic nephropathy (53, 56 and 63% in normoalbuminuria, microalbuminuria and proteinuria/CRF, respectively), these differences were not significant.
|
12897091 |
2003 |
|
rs1217691063
|
|
|
0.100 |
GeneticVariation |
BEFREE |
Our findings indicate that the MTHFR 677C>T polymorphism may be associated with an elevated risk for CVD in ESRD patients, especially among Asians.
|
25050994 |
2014 |
|
rs1217691063
|
|
|
0.100 |
GeneticVariation |
BEFREE |
The genotype of the MTHFR gene in 106 patients with ESRD was homozygous C677T mutation (VV) in 17 patients (16.1%) and heterozygous (AV) in 63 patients (58.4%); 26 patients (24.5%) did not carry this mutation (AA).
|
10430972 |
1999 |
|
rs1217691063
|
|
|
0.100 |
GeneticVariation |
BEFREE |
We found no evidence for survival bias due to C677T genotype in the ESRD cohort, or bias due to genetically determined accelerated progression to novel microalbuminuria in the controls.
|
17005529 |
2007 |
|
rs1217691063
|
|
|
0.100 |
GeneticVariation |
BEFREE |
In this case-control, cross-sectional study the frequency of the MTHFR 677C --> T and the 1298A --> C polymorphism was compared between patients with hypertension-related chronic renal failure (n = 90), patients with essential hypertension without kidney injury (n = 90), and healthy individuals (n = 90) who were matched for age and gender.
|
16280279 |
2005 |
|
rs1217691063
|
|
|
0.100 |
GeneticVariation |
BEFREE |
The combined effects of renal failure, folate and vitamin B(12) levels, and a common mutation (C677T) in the methylenetetrahydrofolate reductase (MTHFR) gene that leads to total plasma homocysteine (tHcy) elevation in CRF children were investigated.
|
12644913 |
2003 |
|
rs1217691063
|
|
|
0.100 |
GeneticVariation |
BEFREE |
The C677T genotype of MTHFR is associated with CVD in ESRD and may be a more meaningful marker than tHcy for abnormal homocysteine metabolism in ESRD.
|
11532106 |
2001 |
|
rs1799983
|
|
|
0.100 |
GeneticVariation |
BEFREE |
These data indicated that Glu298Asp is the predisposing factor in ESRD, especially DM-derived ESRD.
|
12364359 |
2002 |
|
rs1799983
|
|
|
0.100 |
GeneticVariation |
BEFREE |
The evidence accumulated suggested that 4b/a and G894T polymorphisms in the eNOS gene were associated with ESRD susceptibility, indicating that 4a and T allele carriers might become significant genetic molecular markers for the onset of ESRD in overall populations.
|
24673298 |
2014 |
|
rs1799983
|
|
|
0.100 |
GeneticVariation |
BEFREE |
The GLU298ASP variant of nitric oxide synthase interacts with asymmetric dimethyl arginine in determining cardiovascular mortality in patients with end-stage renal disease.
|
16148605 |
2005 |
|
rs1799983
|
|
|
0.100 |
GeneticVariation |
BEFREE |
It appears that Glu298Asp may be a predisposing factor in DM-derived and HT-derived ESRD.
|
18793530 |
2008 |
|
rs1799983
|
|
|
0.100 |
GeneticVariation |
BEFREE |
The endothelial nitric oxide synthase Glu298Asp and Asp29Asp genotypes were significantly more frequent in rapid progressors (9.6% (7/73) Asp/Asp, 39.7% (29/73) Asp/Glu, 50.7% (37/73) Glu/Glu) and in ADPKD group with ESRF between 40-63 years (11.3% (16/142) Asp/Asp, 41.5% (59/142) Asp/Glu, 47.2% (67/142) Glu/Glu) in comparison with slow progressors (8.8% (8/91) Asp/Asp, 24.2% (22/91) Asp/Glu, 67.0% (61/91) Glu/Glu) and with control group (8% Asp/Asp, 32% Asp/Glu, 60% Glu/Glu) (Chi-square test, p<0.05).
|
15287194 |
2004 |
|
rs1799983
|
|
|
0.100 |
GeneticVariation |
BEFREE |
Atherosclerosis and the Glu298Asp polymorphism of the eNOS gene in white patients with end-stage renal disease.
|
16364824 |
2005 |
|
rs1799983
|
|
|
0.100 |
GeneticVariation |
BEFREE |
Since the Glu298Asp variant in the eNOS gene alters caveolar localization of the corresponding enzyme, we tested the interaction between this variant and the rs4730751 polymorphism of the caveolin-1 (CAV-1) gene as related to arterial remodeling in end-stage renal disease (ESRD) patients.
|
21976276 |
2012 |
|
rs1799983
|
|
|
0.100 |
GeneticVariation |
BEFREE |
We tested the relationship between carotid intima-media thickness (IMT) and three endothelial NO synthase (eNOS) polymorphisms (G894T, T-786C, and 27-bp repeat in intron 4) in an ethnically and geographically homogeneous group of 147 patients with ESRD.
|
17586410 |
2007 |
|
rs1799983
|
|
|
0.100 |
GeneticVariation |
BEFREE |
However, a link between eNOS Glu298Asp gene polymorphism and ESRD risk was not found in Caucasians and Brazil population.
|
23464568 |
2013 |